Browse the corpus

REFERENCES Artymowicz RJ and James VE, “Atovaquone: A New Antipneumocystis Agent,” Clin Pharm , 1993, 12(8):563-70. [PubMed 8222520 ] Behbahani R, Moshfeghi M, and Baxter JD, “Therapeutic Approaches for AIDS-Related Toxoplasmosis,” Ann Pharmacother , 1995, 29(7-8):760-8. [PubMed 8520094 ] Centers for Disease Control and Prevention, “Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children: Recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,” MMWR Recomm Rep , 2009, 58(RR-11):1-166. Available at file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf [PubMed 19730409 ] El-Sadr WM, Murphy RL, Yurik TM, et al, “Atovaquone Compared With Dapsone for the Prevention of Pneumocystis carinii in Patients With HIV Infection Who Cannot Tolerate Trimethoprim, Sulfonamides, or Both,” N Engl J Med , 1998, 339(26):1889-95. [PubMed 9862944 ] “Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-infected Adults and Adolescents. Panel on Clinical Practices for Treatment of HIV Infection,” June 18, 2008. Available at file://www.aidsinfo.nih.gov Haile LG and Flaherty JF, “Atovaquone: A Review,” Ann Pharmacother , 1993, 27(12):1488-94. [PubMed 8305784 ] Hughes W, Leoung G, Kramer F, et al, “Comparison of Atovaquone (566C80) With Trimethoprim-Sulfamethoxazole to Treat Pneumocystis carinii Pneumonia in Patients With AIDS,” N Engl J Med , 1993, 328(21):1521-7. [PubMed 8479489 ] Katlama C, Mouthon B, Gourdon D, et al, “Atovaquone as Long-term Suppressive Therapy for Toxoplasmic Encephalitis in Patients With AIDS and Multiple Drug Intolerance. Atovaquone Expanded Access Group,” AIDS , 1996, 10(10):1107-12. [PubMed 8874627 ] Pagano G, Kennedy W, Weller S, et al, “The Safety and Pharmacokinetics of Atovaquone in Immunocompromised Children,” Abstracts of the IX International Conference on AIDS in Affiliation With the IV STD World Congress: Berlin, 1993, June 6-11; Abs No PO-B10-1455. Spencer CM and Goa KL, “Atovaquone. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Opportunistic Infections,” Drugs , 1995, 50(1):176-96. [PubMed 7588086 ] Vannier E and Krause PJ, “Human Babesiosis,” N Engl J Med , 2012, 366(25):2397-2407. [PubMed 22716978 ]

Pagano G, Kennedy W, Weller S, et al, “The Safety and Pharmacokinetics of Atovaquone in Immunocompromised Children,” Abstracts of the IX International Conference on AIDS in Affiliation With the IV STD World Congress: Berlin, 1993, June 6-11; Abs No PO-B10-1455. Spencer CM and Goa KL, “Atovaquone. A Review of Its Pharmacological Properties and Therapeutic Efficacy in Opportunistic Infections,” Drugs , 1995, 50(1):176-96. [PubMed 7588086 ] Vannier E and Krause PJ, “Human Babesiosis,” N Engl J Med , 2012, 366(25):2397-2407. [PubMed 22716978 ] Topic 8957 Version 40.0 © 2013 UpToDate, Inc. All rights reserved. | Subscription and License Agreement | Release: 21.6- C21.56 Licensed to: AsanBook Dig. Med. Lib. | Support Tag: [0604-58.240.98.179-2FE80B8408-S244013.14]